Licensing Agreement

Eligen technology company, Novartis enter into option and license agreement

Published in Biotech Business Week, December 27th, 2004

Emisphere Technologies, Inc., (EMIS) announced that it has received $10 million from Novartis Pharma, AG, in exchange for a convertible note, in conjunction with an option and license agreement between Novartis and Emisphere entered into for the development and commercialization of an oral form of parathyroid hormone (PTH) by Novartis using Emisphere's eligen delivery technology.

Emisphere is currently engaged in litigation with Eli Lilly and Co. concerning the termination of the existing oral PTH collaboration between the two companies. Novartis has acquired an option to license Emisphere's eligen technology for the development of an oral PTH that is dependent upon,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Biotech Business Week

Source: Biotech Business Week (2004-12-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry